BioSpace News Archive

Bristol Myers Squibb announced the first disclosure of primary analysis results from two pivotal studies, TRANSCEND FL, an open-label, global, multicenter, Phase 2, single-arm study evaluating Breyanzi in patients with relapsed or refractory follicular lymphoma and the relapsed or refractory mantle cell lymphoma cohort of TRANSCEND NHL 001, an open-label, multicenter, Phase 1, single-arm, seamless-design study evaluating Breyanzi.

Seres Therapeutics, Inc. and Nestlé Health Science announced the presentation of a post-hoc analysis from the Phase 3 development program for VOWST™, the first and only U.S. Food and Drug Administration -approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI.

Horizon Therapeutics plc announced the presentation of new data from the randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA in patients with long disease duration and low Clinical Activity Score, a measure of disease activity.

Rhythm Pharmaceuticals, Inc. announced data that showed meaningful weight loss was sustained and progressed in patients with hypothalamic obesity treated with setmelanotide for six months as part of the long-term extension of its Phase 2 trial.

Horizon Therapeutics plc announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves’ disease and TED, including among those treated with TEPEZZA.

Ascendis Pharma A/S reported one-year data from its ongoing Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism.

IASO Biotechnology announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its IASO-782 Injection for use in U.S. clinical trials for Autoimmune hematological disorders, including primary immune thrombocytopenia and warm autoimmune hemolytic anemia.

Chinook Therapeutics, Inc. announced a free communication presentation on CHK-336 presented at the 60th ERA Congress being held virtually and live in Milan, Italy.

Vera Therapeutics, Inc. announced the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through week 36.

Sling Therapeutics, Inc. announced the presentation of data demonstrating that linsitinib, a small molecule insulin-like growth factor I receptor inhibitor, prevented TED progression in a mouse model of TED, regardless of when treatment was administered.